期刊文献+

转化生长因子β1T869C基因多态性与子宫内膜异位症

Polymorphism of transforming growth factor β1 T869C gene and endometriosis
原文传递
导出
摘要 目的:探讨转化生长因子TGFβ1T869C基因多态性及其血清水平与子宫内膜异位症的关系。方法:用聚合酶链反应扩增TGFβ1T869C基因片段,PstⅠ内切酶进行限制性酶切反应并经测序证实。结果:子宫内膜异位症组TGFβ1 T869 C/C、C/T、T/T表型频率分别为0.210 0、0.600 0、0.190 0,对照组分别为0.250 0、0.580 0、0.170 0;子宫内膜异位症组TGFβ1 T869C、TGFβ1 T869T基因频率分别为0.510 0、0.490 0。对照组分别为0.540 0、0.460 0,TGFβ1T869C各种基因型频率在内异症组与对照组之间的差异无统计学意义(P>0.05)。结论:TGFβ1T869C基因多态性与子宫内膜异位症无关联。 Objective:To explore the relationship between tumor necrosis factor(TGF) β1T869C gene polymorphism,its serum level and endometriosis. Methods:PCR was used to amplify the fragments of TGF β1T869C gene,RELP was performed by Pst Ⅰ endonuclease,then the results were confirmed by gene sequencing. Results:The frequencies of TGF β1 T869 C/C,C/T,T/T phenotypes in endometriosis group were 0.210 0,0.600 0 and 0.190 0,respectively,while in control group,the frequencies were 0.250 0,0.580 0 and 0.170 0,respectively;the gene frequencies of TGFβ1 T869C and TGFβ1 T869T in endometriosis group were 0.510 0 and 0.490 0,respectively,while in control group,the frequencies were 0.540 0 and 0.460 0,respectively;there was no significant difference in the frequencies of various TGF β1T869C genotypes between endometriosis group and control group(P0.05). Conclusion:There is no correlation between TGF β1T869C gene polymorphism and endometriosis.
出处 《中国妇幼保健》 CAS 北大核心 2011年第21期3307-3310,共4页 Maternal and Child Health Care of China
关键词 子宫内膜异位症 转化生长因子TGFβ1 T869C 多态性 Endometriosis Tumor necrosis factor β1 T869C Polymorphism
  • 相关文献

参考文献8

  • 1高春芳.TGFβ1基因变异与疾病相关性研究展望[J].世界华人消化杂志,2007,15(28):2959-2965. 被引量:13
  • 2Hsieh YY, Chang CC, Tsai FJ, et al. Polymorphism for transfrming growth factor beta 1 - 509 ( TGF - B1 - 509 ) : association with endome-triosis [J]. Biochem Genet, 2005, 43 (5-6): 203.
  • 3Kim JJ, Choi YM, Choung SH, et al. Analysis of the transtbrming growth factor beta 1 gene -509 C/T polymorphism in patients with ad- vanced - stage endometriosis [J].Fertil Steril, 2009 : 25.
  • 4van Kaam K J, Romano A, Dunsehnan CA. Transforming growth factor beta 1 gene polymorphism 509C/T in deep infiltrating endometriosis [J]. Reprod Sci, 2007, 14 (4) : 367.
  • 5Pizzo A, Salmeri FM, Ardita FV, et al. Behaviour of cytokine levels in serum and peritoneal fluid of women with endometriosiss [J]. Gynecol Obstet Invest, 2002, 54 (2): 82.
  • 6Loven'o G, Maiorano E, Napoli A, et al. Transfbrming growth factor-beta 1 and insulin - like growth factor - 1 expression in ovarian endom- etriotic cysts: a preliminary study [J]. International Journal of Molec- ular Medicine, 2001, 7 (4): 423.
  • 7Komiyama S, Aoki D, Komiyama M. Local activation of TGF - beta I at endometriosis sites [J]. J Reprod Med, 2007, 52 (4): 306.
  • 8Omwandho CO, Konrad L, Halis G, et al. Role of TGF -betas in nor- mal human endometrium and endometriosis[J]. Hum Reprod, 2010, 25 (1) : 101.

二级参考文献52

  • 1杨再兴,王皓,高春芳,徐玲玲,赵文静.转化生长因子β1基因多态性对乙型肝炎肝硬化的影响[J].中华医学杂志,2005,85(15):1021-1026. 被引量:28
  • 2Gressner AM, Weiskirchen R. Modem pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006; 10:76-99.
  • 3Wahl SM, Wen J, Moutsopoulos N. TGF-beta: a mobile purveyor of immune privilege. Immunol Rev 2006; 213:213-227.
  • 4Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006; 24: 99-146.
  • 5Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, Roberts AB, Sporn MB, Thorgeirsson SS. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A 1995; 92:2572-2576.
  • 6Kanzler S, Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P, Rose-John S, zum Buschenfelde KH, Blessing M. TGF-betal in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physio11999; 276:G1059-1068.
  • 7Ueberham E, Low R, Ueberham U, Schonig K, Bujard H, Gebhardt R. Conditional tetracycline- regulated expression of TGF-betal in liver of transgenic mice leads to reversible intermediary fibrosis. Hepatology 2003; 37: 1067-1078.
  • 8Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci U S A 1999; 96:2345-2349.
  • 9Ueno H, Sakamoto T, Nakamura T, Qi Z, Astuchi N, Takeshita A, Shimizu K, Ohashi H. A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats. Hum Gene Ther 2000; 11:33-42.
  • 10George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 1999; 96: 12719-12724.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部